Associations between genetic mutations in different SARS-CoV-2 strains and negative conversion time of viral RNA among imported cases in Hangzhou: A cross-sectional studyArticle Published on 2024-05-202024-09-05 Journal: Virus Research [Category] update2024, [키워드] genetic mutation imported cases Negative conversion SARS-CoV-2 strain [DOI] 10.1016/j.virusres.2024.199400 PMC 바로가기 [Article Type] Article
Factors associated with negative conversion of viral RNA in hospitalized children infected with SARS-CoV-2 Omicron variant in Shanghai, China: a retrospective analysisarticle Published on 2023-04-262024-09-05 Journal: BMC Infectious Diseases [Category] update2024, [키워드] children Negative conversion Omicron SARS-CoV-2 variant vaccination [DOI] 10.1186/s12879-023-08223-x PMC 바로가기 [Article Type] article
2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trialClinical Trial Published on 2022-08-042022-10-04 Journal: BMC Infectious Diseases [Category] SARS, 임상, [키워드] 2-deoxy-D-glucose 2-DG acute COVID-19 addition Administered adverse event age analyzed approach clinical benefit clinical recovery clinical study clinical trial conducted COVID-19 CTRI discharge dose efficacious therapeutic Efficacy Efficacy and safety evaluate evaluated hazard In-vitro intensive care Isolation limit management median metabolic inhibitor Mild moderate Mortality Negative conversion Normalisation Open-label outcomes Patient progression randomised randomised clinical trial Randomized receive reported RT-PCR SARS-CoV-2 severe COVID-19 severe COVID-19 patients shown significantly shorter standard care Standard of care time Tolerability treated Treatment Trial vital sign WHO [DOI] 10.1186/s12879-022-07642-6 PMC 바로가기 [Article Type] Clinical Trial
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trialClinical Trial Published on 2022-06-012022-10-05 Journal: Enfermedades infecciosas y microbiologia clinica ( [Category] COVID19(2023년), SARS, 임상, [키워드] 95%CI Admission asked benefit both groups clinical symptom Comorbidities contraindication Control control group COVID-19 decrease diarrhea died Disease progression Efficacy and safety English female FIVE Follow-up HCQ Health Health care worker Healthcare professional healthcare worker Healthcare workers Hidroxicloroquina Hospitalization Hydroxychloroquine in both groups in viral Infección por SARS-CoV-2 initial intensive care unit Loading dose media median age Mild mild SARS-CoV-2 infection Negative conversion no significant difference non-randomized non-randomized trial outcome outpatients Pacientes externos Patient PCR Pneumonia primer Probability professional Prospective prospectivo reduction in required SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 viral load Side effect significant difference Spanish Symptom Trabajadores sanitarios. Treatment treatment group Two patient viral dynamics were given [DOI] 10.1016/j.eimce.2020.10.015 PMC 바로가기 [Article Type] Clinical Trial
Longitudinal, virological, and serological assessment of hospitalized COVID-19 patients입원한 COVID-19 환자의 종단, 바이러스 및 혈청학적 평가Article Published on 2022-02-012022-09-11 Journal: Journal of Neurovirology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Admission anal swabs anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 IgM Antibody titers Blood blood sample Blood samples Cohort collected COVID-19 pandemic COVID-19 patient COVID-19 patients described discharge ELISA evaluated Evidence First wave healthcare Hospital admission Hospitalized hospitalized COVID-19 patient IgG antibody titer IgG antibody titers IgG levels IgM and IgG implication Italy longitudinal median time nasopharyngeal nasopharyngeal swabs Negative conversion NPs Patient patients positive provide qRT-PCR RNA SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 RNA detection serological assessment seropositive serum sample serum samples significantly Swab tested the median Virological [DOI] 10.1007/s13365-021-01029-0 PMC 바로가기 [Article Type] Article
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan대만의 COVID-19 환자 치료를 위한 오프라벨 사용에서 Ropeginterferon Alfa-2b의 임상 경험Article Published on 2022-02-012022-09-11 Journal: Advances in therapy [Category] COVID19(2023년), SARS, 치료제, [키워드] Administered age clinical coronavirus COVID-19 COVID-19 patients disease Effectiveness Efficacy evaluated experience interferon knowledge median Mild Moderate COVID-19 moderate COVID-19 patients moderate disease Negative conversion outcome Patient patients patients with moderate Pegylated interferon phase positive Primary outcome Randomized receiving Retrospective study Ropeginterferon Alfa-2b RT-PCR SARS-CoV-2 RT-PCR single dose Standard of care statistically significant subcutaneously Taiwan Treatment [DOI] 10.1007/s12325-021-01998-y PMC 바로가기 [Article Type] Article
Demographic, Virological Characteristics and Prognosis of Asymptomatic COVID-19 Patients in South ChinaMedicine Published on 2022-01-282022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] age ALT Asymptomatic Asymptomatic case asymptomatic patients B.1 B.1.1 B.1.1.7 B.1.351 B.6 Characteristics China chronic liver disease Community Comorbidity country COVID-19 COVID-19 patient demographic develop Epidemiology Genotype Guangdong Hospitalization Hospitalized hypertension infected cases information Laboratory less Lineage lymphocyte Negative conversion Patient patients PCT Prognosis Region Result RNA SARS-CoV-2 SARS-CoV-2 RNA significantly South Subtypes symptomatic Symptomatic patients the SARS-CoV-2 Total Transmission turn variant variants Virological virus WBC [DOI] 10.3389/fmed.2022.830942 PMC 바로가기 [Article Type] Medicine
Communication Pattern Changes Along With Declined IGF1 of Immune Cells in COVID-19 Patients During Disease Progression질병 진행 중 COVID-19 환자의 면역 세포 IGF1 감소와 함께 의사 소통 패턴 변화Immunology Published on 2022-01-142022-09-11 Journal: Frontiers in Immunology [Category] 치료기술, 치료제, [키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis analyzed cause Cell change changed chemokine chemokines communication communication pattern Contact coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 Crosstalk Cytokines described feature growth factor IGF1 Immune cell immune cells immune response immune system Inflammatory Inflammatory cytokine Inflammatory cytokines insulin-like growth factor less mononuclear cell Most patient Most patients Negative conversion pandemic Patient pattern PBMC Peripheral blood Regulatory respiratory reveal SARS-CoV-2 SARS-CoV-2 RNA Serum level serum levels severe acute respiratory syndrome Coronavirus Signal transduction single-cell sequencing stages status Symptoms T cell T cells therapeutic target therapeutic targets [DOI] 10.3389/fimmu.2021.729990 PMC 바로가기 [Article Type] Immunology
Not Only High Number and Specific Comorbidities but Also Age Are Closely Related to Progression and Poor Prognosis in Patients With COVID-19Medicine Published on 2022-01-072022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] age cardiovascular disease Characteristics CHB Chinese Chronic Hepatitis B Chronic kidney disease chronic obstructive CKD clinical clinician Comorbidities Comorbidity COPD Coronavirus disease 2019 (COVID-19) correlated correlation Correlation analysis COVID-19 COVID-19 patient COVID-19 patients CVD Diabetes Mellitus died disease Disease progression disease severity eight Factor Fatty liver FIVE Gout group groups hypertension NAFLD Negative conversion number number of comorbidities number of comorbidity Older outcome outcomes patients with comorbidity patients with COVID-19 Poor poor prognosis predict Predictive Prognosis progression pulmonary disease severe COVID-19 patients Specific virus were assessed [DOI] 10.3389/fmed.2021.736109 PMC 바로가기 [Article Type] Medicine
Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathwayYindan Jiedu 과립은 NF-κB 신호 전달 경로를 억제하여 신종 코로나바이러스 감염증(COVID-19) 환자에서 항염증 효과를 나타냅니다.Randomized Controlled Trial Published on 2022-01-012022-09-11 Journal: Phytomedicine : international journal of phytother [Category] SARS, 유전자 메커니즘, 임상, [키워드] accompanied Activation acute lung injury amyloid A Analysis animals anti-inflammatory effect Anti-inflammatory effects assigned caused CD4 cells clinical Clinical research Compound compounds control group coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 progression Cytokines death decrease disease dissipation docking Effect enrichment analysis erythrocyte sedimentation erythrocyte sedimentation rate evaluate evaluated Factor Granule high-performance liquid chromatography histological HPLC IL-1β IL-6 immune in vitro increase in Inflammation Inflammatory Inflammatory cytokine Inflammatory cytokines inflammatory factors inhibit inhibiting Interaction IκBα kaempferol lesion Ligand ligands lipopolysaccharide lung Lung injury Luteolin mass spectrometry mechanism mechanism of action molecular docking Negative conversion network model NF-κB NF-κB pathway NF-κB signaling NF-κB signaling pathway nuclear translocation nucleic acid overlapping p65 pandemic participant pathway Patient Pharmacology Pharmacology analysis Phosphorylation progression propensity score matching PSM quercetin Randomly recruited sedimentation rate serum serum amyloid significantly strong interaction suppressed T cell Tandem mass spectrometry target targets therapeutic effect therapeutic effects TNF-α viral nucleic acid were measured Yindan jiedugranules. [DOI] 10.1016/j.phymed.2021.153784 PMC 바로가기 [Article Type] Randomized Controlled Trial